Views

CrossRef citations to date

Altmetric

ORIGINAL RESEARCH

Multi-Center Study: The Biochemical Efficacy, Safety and Tolerability of a New α₁-Proteinase Inhibitor, Zemaira

James M. Stocks The University of Texas Health Center at Tyler, Tyler, Texas, USA

Mark Brantly Department of Pulmonary Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

David Pollock Department of Pulmonary Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Alan Barker Pulmonary & Critical Care, Oregon Health and Science University, PortlandUSA

Friedrich Kueppers The Lung Center at Temple University Hospital, Philadelphia, Pennsylvania, USA

Charlie Strange Medical University of South Carolina, Charleston, South Carolina, USA

James F. Donohue Division of Pulmonary Disease & Critical Care, University of NC at Chapel Hill, Chapel Hill, North Carolina, USA

Robert Sandhaus National Jewish Medical and Research Center, Denver, Colorado, USA

show all

Figures & data

Table 1 Assessment schedule

Download CSV Display Table

Table 2 Demographic and baseline characteristics

Download CSV Display Table

Figure 1 Mean ± SD of trough serum antigenic α₁-PI during weeks 7–11.

Figure 1 Mean ± SD of trough serum antigenic α1-PI during weeks 7–11.

Table 3 Summary of ELF antigenic α₁-PI results at baseline and week 11

Download CSV Display Table

Figure 2 Mean ± SD of trough serum antigenic α₁-PI over entire study.

Figure 2 Mean ± SD of trough serum antigenic α1-PI over entire study.

Table 4 Summary of adverse events during 10-week blinded study period. Rates per infusion presented in parentheses

Download CSV Display Table

Table 5 Study drug analysis

Download CSV Display Table

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Multi-Center Study: The Biochemical Efficacy, Safety and Tolerability of a New α₁-Proteinase Inhibitor, Zemaira

Table 1 Assessment schedule

Table 2 Demographic and baseline characteristics

Table 3 Summary of ELF antigenic α₁-PI results at baseline and week 11

Table 4 Summary of adverse events during 10-week blinded study period. Rates per infusion presented in parentheses

Table 5 Study drug analysis

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Multi-Center Study: The Biochemical Efficacy, Safety and Tolerability of a New α1-Proteinase Inhibitor, Zemaira

Figures & data

Table 1 Assessment schedule

Table 2 Demographic and baseline characteristics

Table 3 Summary of ELF antigenic α1-PI results at baseline and week 11

Table 4 Summary of adverse events during 10-week blinded study period. Rates per infusion presented in parentheses

Table 5 Study drug analysis

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Multi-Center Study: The Biochemical Efficacy, Safety and Tolerability of a New α₁-Proteinase Inhibitor, Zemaira

Table 3 Summary of ELF antigenic α₁-PI results at baseline and week 11